Immunitybio is trading at $9.79, up +10.82%, with no clear company-specific announcement identified to explain its September 30 move.
- Recent coverage discusses prior company developments and unconfirmed tokenization speculation, not a new announcement driving the session’s gain.
- The market snapshot shows mixed gains: the Nasdaq is up 0.86%, the S&P 500 0.46%, and the Dow 0.07%. This does not establish a broad-market cause for the much larger stock move.